UnitedHealthcare’s revised IMRT policy for hepatobiliary and pancreatic tumors (effective 2026-03-01) explicitly lists IMRT as medically necessary for unresectable hepatocellular carcinoma, unresectable intrahepatic cholangiocarcinoma, and pancreatic cancer among other primary sites. The policy clarifies exception criteria allowing IMRT when non‑IMRT plans would cause clinically meaningful normal tissue toxicity based on comparative planning or when prior irradiation requires highly conformal re-treatment to respect cumulative organ tolerances. Cited evidence includes a 2023 meta-analysis and retrospective series showing favorable local control and acceptable hepatic toxicity for IMRT in HCC/IHC, and observational data and guidelines supporting IMRT for pancreas to reduce GI toxicity while enabling dose escalation. Providers should document comparative plan results or prior radiation history when requesting exceptions or re‑irradiation coverage under this policy.
UnitedHealthcare Revision: IMRT Coverage and Exception Criteria (MDC 07)
Summary of Revisions in this Document
This UnitedHealthcare Medical Policy (2026T0407HH, effective 2026-03-01) consolidates and clarifies coverage statements for intensity-modulated radiation therapy (IMRT) specifically as it applies to tumors of the hepatobiliary system and pancreas (MDC 07). The policy enumerates primary-site indications for which IMRT is considered "proven and medically necessary," explicitly listing hepatocellular carcinoma, unresectable, intrahepatic cholangiocarcinoma, unresectable, and pancreatic cancer among other tumor sites. The document also restates exception criteria under which IMRT may be considered medically necessary for conditions not enumerated.
The revision emphasizes both the standard covered indications and the pathways for case-by-case exception review: (1) when non-IMRT techniques would increase clinically meaningful normal tissue toxicity as demonstrated by comparative planning, and (2) when prior irradiation of the same or adjacent area requires sculpting of dose to avoid exceeding cumulative normal tissue tolerances. These explicit exception criteria appear as retained or clarified elements guiding coverage decisions for complex hepatobiliary and pancreatic cases.
Coverage Scope: Inclusion of `HCC`, `IHC`, and `Pancreatic Cancer` for IMRT
Coverage Scope for Hepatobiliary and Pancreatic Indications
The policy lists IMRT for definitive therapy of multiple primary sites and explicitly includes , , and as proven and medically necessary indications. IMRT is presented alongside other tumor sites (e.g., head and neck, esophagus, CNS, prostate) where IMRT is considered standard-of-care for definitive treatment of the primary site.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.